Caprock Group LLC Makes New $66,000 Investment in AEON Biopharma, Inc. (NASDAQ:AEON)

Caprock Group LLC bought a new position in AEON Biopharma, Inc. (NASDAQ:AEON) in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor bought 62,686 shares of the company’s stock, valued at approximately $66,000. Caprock Group LLC owned approximately 0.16% of AEON Biopharma as of its most recent filing with the SEC.

Separately, Vanguard Group Inc. lifted its position in AEON Biopharma by 261.8% during the 1st quarter. Vanguard Group Inc. now owns 758,992 shares of the company’s stock valued at $8,804,000 after acquiring an additional 549,207 shares during the period. 22.78% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a “buy” rating and set a $5.00 target price on shares of AEON Biopharma in a research note on Tuesday, October 1st.

AEON Biopharma Trading Up 4.9 %

AEON Biopharma stock opened at $0.56 on Tuesday. AEON Biopharma, Inc. has a 12 month low of $0.52 and a 12 month high of $17.17. The company has a market capitalization of $22.23 million, a price-to-earnings ratio of 3.09 and a beta of 0.40. The business’s fifty day simple moving average is $0.89 and its two-hundred day simple moving average is $1.20.

AEON Biopharma Profile

AEON Biopharma, Inc, a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and posttraumatic stress disorder.